---
figid: PMC5727303__BPH-174-4666-g002
figlink: /pmc/articles/PMC5727303/figure/bph13890-fig-0002/
number: F2
caption: Inhibitors of Wnt signalling. (A) Following Wnt/FZD receptor binding (not
  shown), recruitment of the scaffolding protein AXIN to the receptor complex leads
  to inhibition of GSK3B and the β‐catenin destruction complex, which allows newly
  synthesized β‐catenin to accumulate and translocate to the nucleus (orange arrows),
  where it binds with co‐factors to form a transcriptionally active complex. Indicated
  are some of the inhibitors that target various intracellular nodes of Wnt signal
  transduction that could have therapeutic benefit for gastric cancer patients with
  APC, AXIN or CTNNB1 mutations. (B) Wnt signalling (WNT) can be inhibited at the
  cell surface by various pathway inhibitors such as sFRPs and DKK, which bind to
  Wnt and LRP5/6 respectively. Other approaches target Wnt signalling using small
  molecules that inhibit porcupine (PORCN), which prevent the secretion of Wnt from
  the endoplasmic reticulum (yellow arrow). In addition, FZD receptor‐blocking antibodies
  (vantictumab) and decoy FZD receptors (ipafricept) inhibit Wnt signalling by blocking
  FZD receptors and sequestering Wnts respectively. Gastric cancer patients with RNF43
  mutations or overexpression of Wnt and/or FZD receptors would probably benefit from
  these types of Wnt inhibitors.
pmcid: PMC5727303
papertitle: 'Winding back Wnt signalling: potential therapeutic targets for treating
  gastric cancers.'
reftext: Dustin J Flanagan, et al. Br J Pharmacol. 2017 Dec;174(24):4666-4683.
pmc_ranked_result_index: '13110'
pathway_score: 0.9209811
filename: BPH-174-4666-g002.jpg
figtitle: Inhibitors of Wnt signalling
year: '2017'
organisms: Homo sapiens
ndex: 3f4d9fd6-df0a-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5727303__BPH-174-4666-g002.html
  '@type': Dataset
  description: Inhibitors of Wnt signalling. (A) Following Wnt/FZD receptor binding
    (not shown), recruitment of the scaffolding protein AXIN to the receptor complex
    leads to inhibition of GSK3B and the β‐catenin destruction complex, which allows
    newly synthesized β‐catenin to accumulate and translocate to the nucleus (orange
    arrows), where it binds with co‐factors to form a transcriptionally active complex.
    Indicated are some of the inhibitors that target various intracellular nodes of
    Wnt signal transduction that could have therapeutic benefit for gastric cancer
    patients with APC, AXIN or CTNNB1 mutations. (B) Wnt signalling (WNT) can be inhibited
    at the cell surface by various pathway inhibitors such as sFRPs and DKK, which
    bind to Wnt and LRP5/6 respectively. Other approaches target Wnt signalling using
    small molecules that inhibit porcupine (PORCN), which prevent the secretion of
    Wnt from the endoplasmic reticulum (yellow arrow). In addition, FZD receptor‐blocking
    antibodies (vantictumab) and decoy FZD receptors (ipafricept) inhibit Wnt signalling
    by blocking FZD receptors and sequestering Wnts respectively. Gastric cancer patients
    with RNF43 mutations or overexpression of Wnt and/or FZD receptors would probably
    benefit from these types of Wnt inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FZD8
  - FZD3
  - GSK3B
  - FZD1
  - FZD9
  - FZD7
  - FZD5
  - WNT1
  - WNT2
  - GSK3A
  - FZD6
  - WNT6
  - LRP5
  - FZD4
  - LRP6
  - WNT9A
  - WNT9B
  - APC
  - FZD2
  - WNT5A
  - WNT5B
  - WNT10A
  - WNT3
  - AXIN1
  - EP300
  - WNT4
  - WNT7A
  - WNT2B
  - WNT16
  - WNT8A
  - WNT11
  - TNKS
  - WNT7B
  - FZD10
  - CTNNB1
  - WNT8B
  - WNT3A
  - KRT10
  - AXIN2
  - WNT10B
  - BCL9
  - CGP049090
  - Cancer
genes:
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD8
  entrez: '8325'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD3
  entrez: '7976'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD1
  entrez: '8321'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD9
  entrez: '8326'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD7
  entrez: '8324'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD5
  entrez: '7855'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT1
  entrez: '7471'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT2
  entrez: '7472'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3A
  entrez: '2931'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD6
  entrez: '8323'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT6
  entrez: '7475'
- word: LRP5/6
  symbol: LRP5
  source: hgnc_symbol
  hgnc_symbol: LRP5
  entrez: '4041'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD4
  entrez: '8322'
- word: LRP5/6
  symbol: LRP6
  source: hgnc_symbol
  hgnc_symbol: LRP6
  entrez: '4040'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT9A
  entrez: '7483'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT9B
  entrez: '7484'
- word: APC
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD2
  entrez: '2535'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT5A
  entrez: '7474'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT5B
  entrez: '81029'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT10A
  entrez: '80326'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT3
  entrez: '7473'
- word: Axin
  symbol: AXIN
  source: bioentities_symbol
  hgnc_symbol: AXIN1
  entrez: '8312'
- word: p300
  symbol: p300
  source: hgnc_alias_symbol
  hgnc_symbol: EP300
  entrez: '2033'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT4
  entrez: '54361'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT7A
  entrez: '7476'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT2B
  entrez: '7482'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT16
  entrez: '51384'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT8A
  entrez: '7478'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT11
  entrez: '7481'
- word: TNKS
  symbol: TNKS
  source: hgnc_symbol
  hgnc_symbol: TNKS
  entrez: '8658'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT7B
  entrez: '7477'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD10
  entrez: '11211'
- word: B-catenin
  symbol: beta-catenin
  source: hgnc_alias_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT8B
  entrez: '7479'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT3A
  entrez: '89780'
- word: CK10
  symbol: CK10
  source: hgnc_alias_symbol
  hgnc_symbol: KRT10
  entrez: '3858'
- word: Axin
  symbol: AXIN
  source: bioentities_symbol
  hgnc_symbol: AXIN2
  entrez: '8313'
- word: WNT
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT10B
  entrez: '7480'
- word: BCL9
  symbol: BCL9
  source: hgnc_symbol
  hgnc_symbol: BCL9
  entrez: '607'
chemicals:
- word: CGP049090
  source: MESH
  identifier: C538948
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC5727303__F2
redirect_from: /figures/PMC5727303__F2
figtype: Figure
---
